Key result
Genomic and personalized medicine for hypertension management requires a paradigm shift toward integrated and holistic approaches for better prevention and treatment.
This review highlights the need for a paradigm shift toward integrated and holistic approaches in personalized hypertension management.
Clinicians should await validation trials before genomic hypertension strategies; leaves open their integration into routine care.
The revolution occurring in genomic and personalized medicine is likely to have a significant impact on the management of hypertension. However, from the perspective of translating new knowledge into clinical practice, progress has been slow. This review article summarizes recent advances in hypertension-related diagnostics while also offering new perspective on hypertension management for the future. Such new perspectives will likely require a paradigm shift toward more integrated and holistic approaches for better prevention and treatment of hypertension in both individuals and the population as a whole.
No takes yet. Share an insight, caveat, or question.
Gladding et al. (2015) conducted a review in Hypertension. Personalized medicine was evaluated. Genomic and personalized medicine for hypertension management requires a paradigm shift toward integrated and holistic approaches for better prevention and treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: